Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy  by Dasta, Joseph F. et al.
Thrombosis Research 135 (2015) 303–310
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresRegular ArticleDaily Hospitalization Costs in Patients with Deep Vein Thrombosis or
Pulmonary Embolism Treated with Anticoagulant TherapyJoseph F. Dasta a, Dominic Pilon b, Samir H. Mody c, Jessica Lopatto c, François Laliberté b, Guillaume Germain b,
Brahim K. Bookhart c, Patrick Lefebvre b, Edith A. Nutescu d
a University of Texas College of Pharmacy, Round Rock, TX USA
b Groupe d’analyse, Ltée, Montréal, QC, Canada
c Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA
d The University of Illinois at Chicago College of Pharmacy, Chicago, IL, USAhttp://dx.doi.org/10.1016/j.thromres.2014.11.024
0049-3848/© 2014 The Authors. Published by Elsevier Ltda b s t r a c ta r t i c l e i n f oArticle history:
Received 19 August 2014
Received in revised form 28 October 2014
Accepted 29 November 2014
Available online 4 December 2014
Keywords:
Costs and cost analysis
Hospitalization
Hospital costs
Pulmonary embolism
Venous thrombosis
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary em-
bolism (PE), affects about 900,000 persons in the United States each year.
Objectives: To quantify the progression of daily hospitalization costs among DVT and PE patients.
Patients/Methods: A retrospective claims analysis was conducted from 01/01/2009 to 03/01/2013 using the
Premier Perspective Comparative Hospital Database. Patients≥18 years of age with an admitting/primary diag-
nosis of DVT or PE and receiving anticoagulant therapy were identiﬁed. Treatment patterns, mean daily costs,
and total hospitalization costs were reported for the DVT and PE populations. Comparisons of mean daily costs
with those of the previous day were presented to identify statistical cost differences between hospitalization
days.
Results: A total of 28,953 and 35,550 patients were identiﬁed with a diagnosis of DVT and PE, respectively. The
daily costswere at their highest during the ﬁrst three days for DVT patients at $2,321, $1,875, and $1,558, respec-
tively. Similar results were found for PE patients with costs at their highest in the ﬁrst three days, at $2,981,
$2,034, and $1,564, respectively. Among the DVT and PE populations, mean daily costs were $1,594 and
$1,735, respectively, and daily hospitalization costs became stable on the third day of the hospitalization
(standardized differences b10%).
Conclusions: Daily hospitalization costs of patients with an admitting/primary diagnosis of DVT or PE were high
in the ﬁrst days and became stable on the third day. It was further suggested that any change in the LOS could
signiﬁcantly affect hospitalization costs.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Venous thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE), affects about
900,000 persons in the United States each year and about 300,000
of these persons die from this disease [1]. In addition, the number
of adults with VTE in the United States is estimated to double to
1.82million by 2050 [2]. VTE is a costly disease with an estimated an-
nual cumulative cost ranging from $4.9 to $7.5 billion for DVT and
$8.5 to $19.8 billion for PE [3]. Study results based on large US data-
bases have reported a cost ranging from $3,000 to $9,500 for ﬁrst VTE
hospitalization [4]. Hospitalization costs are the main cost driver for
VTE patients, contributing about half of the total annualized costs per
patient [5].
Historically, the standard of care for the treatment of VTE has been
the initial administration of a short acting anticoagulant as a bridging
agent (e.g., heparin or low molecular weight heparin) initiated in. This is an open access article undercombination with a vitamin K antagonist (VKA; e.g., warfarin), then
followed by VKA therapy alone for subacute and chronic therapy
[6]. Recently, target-speciﬁc oral anticoagulants have been evaluat-
ed and introduced for the treatment of DVT and/or PE. Treatment
with target-speciﬁc oral anticoagulants may have the potential to
reduce hospitalization costs compared to treatment with VKA by
reducing the hospital length of stay (LOS) since routine laboratory
monitoring and injectable bridging therapy are not required
[7–10].
To our knowledge, the progression of daily hospitalization costs has
not been studied in a population of DVT and PE patients. Quantifying
daily costs instead of only total hospitalization costs allows for a better
interpretation of the impact of various therapies or strategies that
could prolong or shorten LOS. Therefore, the main objective of this
study was to quantify the progression of daily hospitalization costs
among patients with a primary diagnosis of DVT or PE treated with
anticoagulation therapy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Patient Disposition.
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Data Source
This studywas based on data from the Premier Perspective Compar-
ative Hospital Database covering January 2009 to March 2013. Premier
is the largest hospital-based database in the United States and contains
detailed information formore than 45million inpatient discharges from
over 600 acute-care hospitals across all US regions. Data elements in-
clude patient demographic characteristics, primary and secondary diag-
noses for every hospitalization as well as all procedures, and other
department activities. In comparison to centralized health care claims
recorded by insurance companies, patients’ medical information avail-
able in the Premier database comes from records collected for billing
purposes at the hospital level. Costs are collected by Premier from hos-
pital cost accounting systems and are reported for each billing record
during a hospital stay. Premier data are de-identiﬁed and fully compli-
ant with all HIPAA privacy and security requirements to protect partic-
ipant anonymity and conﬁdentiality. Institutional review board (IRB)
approval and informed consent were not required for this study.
Study Design
A retrospective cohort design was used to evaluate the daily
progression of hospitalization costs for patients diagnosed with DVT
or PE. Patients included in the analysis had to have at least one admit-
ting/primary diagnosis of DVT (ICD-9-CM: 451.1x, 451.2x, 453.xx) or
PE (ICD-9-CM: 415.1x) during a hospitalization. Patients who had
both a DVT and a PE diagnosis were included in the PE cohort. In addi-
tion, patients had to be at least 18 years of age as of the date of the hos-
pital admission and had to have received at least one anticoagulant
treatment during their hospitalization. The observation period for the
analysis corresponded to the patients’ hospital stay. In each cohort, a
sub-analysis was conducted on a sample of patients with an intensive
care unit (ICU) stay during their hospitalization.
Study Endpoints
The primary endpoint of the study was the progression of costs per
hospitalization day and the mean total hospitalization costs. Stratiﬁca-
tion of the hospitalization costs into mutually exclusive categories
(i.e., room and board, nursing, surgery, supply, laboratory, pharmacy,
and other costs) was an exploratory endpoint. In addition, pharmacy
costs were further stratiﬁed into subgroups of costs depending onmed-
ication type.
Statistical Analysis
Descriptive statistics were used to summarize patients’ characteris-
tics evaluated at the index hospital admission. LOS and treatment char-
acteristics (e.g., number of different medications used, days to
anticoagulant therapy administration) were also evaluated during the
hospitalization. For all descriptive statistics, means and medians
(±SDs) were reported for continuous variables, while frequencies and
percentages were reported for categorical variables.
Mean hospitalization costs were reported for each day for the ﬁrst 7
days, andmean daily costswere reported for days ranging fromday 8 to
day 14 and from day 15 to day 30. Overall mean daily hospitalization
costs per patient aswell asmean total hospitalization costswere report-
ed. Using standardized differences, statistical comparisons were made
in order to assess the day of the hospitalizationwhere the costs became
stable (i.e., standardized difference≤10%). The standardized difference
was calculated by dividing the absolute difference in the mean costs of
two consecutive days by their pooled standard deviation (SD). The
pooled SD was calculated as the square root of the average of thesquared SDs [11–13]. All costs were adjusted to the 2013 $US value
based on the medical care component of the Consumer Price Index.
Results
Fig. 1 presents the study sample selection. A total of 66,982 patients
had an admitting/primary for DVT or PE during their hospitalization,
and 64,503were eligible for the study. Therewere 35,550 patients iden-
tiﬁed with a diagnosis of PE. The remaining 28,953 patients were iden-
tiﬁed with a diagnosis of DVT (Fig. 1). The mean (SD) age of the DVT
cohort was 61.5 (18.2) years and 48.8% were female. In the PE cohort,
50.3% of patients were female and the mean (SD) age was 60.0 (17.4)
years (Table 1).
Table 2 presents LOS and treatment characteristics of both cohorts.
The mean [median] (SD) LOS for the DVT and PE cohort was 4.7 [4]
(4.5) days and 5.4 [5] (4.6) days, respectively. Among cohorts, 2,857
(9.9%) of DVT patients and 8,587 (24.2%) of PE patients had an ICU
stay during their hospitalization (Table 2). Patients in both cohorts
were found to take an average of seven different medications per day,
with a medication dose burden of an average of 13 doses administered
per day (Table 2). For both cohorts, themean time from the hospital ad-
mission to the administration of an anticoagulant was 1.3 days
(Table 2).
In the DVT cohort, the mean (SD) daily costs were $1,594 (1,346)
with costs ranging from $2,321 (2,476) to $1,263 (1,967) in the ﬁrst
seven days, the most expensive being the admission day and the least
expensive being the sixth day (Table 3a). The costs stabilized on the
third day of the hospitalization (mean [SD]: $1,558 [2,245]), since the
costs of the fourth day (mean [SD]: $1,398 [2,180])were not statistically
different than those of the third day (standardized difference 7.2%) in
the DVT group. In the PE cohort, the mean (SD) daily costs were
$1,735 (1,211) with costs ranging from $2,981 (2,602) to $1,276
(1,512) in the ﬁrst seven days. As in the DVT cohort, themost expensive
daywas the admission day, while the sixth daywas the least expensive.
In the PE cohort, daily costs also stabilized on the third day after ad-
mission (mean [SD]: $1,564 [1,682]), as the mean (SD) costs of the
fourth day ($1,421 [1,479]) were not statistically different from those
on the third day (standardized difference 9.0%; Table 3a). Among the
stratiﬁed costs, the room and board costswere the biggest cost category
accounting for 40% to 53% of the total costs of the DVT cohort and 38% to
59% of the costs of the PE cohort, depending on the day (Figs. 2 and 3).
Table 1
Patient Demographics and Clinical Characteristics of DVT and PE Patients.
Characteristics DVT PE
(N = 28,953) (N = 35,550)
Demographics1
Age, mean [median] (SD) 61.5 [62.0] (18.2) 60.0 [61.0] (17.4)
Gender, female, n (%) 14,115 (48.8%) 17,864 (50.3%)
Marital status1, n (%)
Married 11,997 (41.4%) 15,923 (44.8%)
Single 13,463 (46.5%) 16,167 (45.5%)
Other/unknown 3,493 (12.1%) 3,460 (9.7%)
Ethnicity1, n (%)
White 19,111 (66.0%) 23,696 (66.7%)
Black 4,163 (14.4%) 5,598 (15.7%)
Other/Unknown 5,679 (19.6%) 6,256 (17.6%)
Primary payer type1, n (%)
Medicare 13,691 (47.3%) 15,477 (43.5%)
Managed Care 7,888 (27.2%) 10,270 (28.9%)
Commercial indemnity 1,902 (6.6%) 2,901 (8.2%)
Medicaid 2,028 (7.0%) 2,525 (7.1%)
Other/Unknown 3,444 (11.9%) 4,377 (12.3%)
Region of hospital1, n (%)
East north central 3,463 (12.0%) 4,544 (12.8%)
East south central 1,610 (5.6%) 1,767 (5.0%)
Middle Atlantic 6,370 (22.0%) 6,731 (18.9%)
Mountain 1,106 (3.8%) 2,297 (6.5%)
New England 614 (2.1%) 935 (2.6%)
Paciﬁc 2,518 (8.7%) 4,361 (12.3%)
South Atlantic 8,219 (28.4%) 9,634 (27.1%)
West north central 1,783 (6.2%) 2,383 (6.7%)
West south central 3,270 (11.3%) 2,898 (8.2%)
Hospital characteristics1, n (%)
Urban (vs. rural) 26,385 (91.1%) 32,293 (90.8%)
Teaching 11,035 (38.1%) 14,050 (39.5%)
Number of beds
b 250 7,556 (26.1%) 9,156 (25.8%)
250-500 12,311 (42.5%) 15,938 (44.8%)
500-750 6,660 (23.0%) 7,225 (20.3%)
N 750 2,426 (8.4%) 3,231 (9.1%)
Admitting physician specialty1, n (%)
Cardiology 693 (2.4%) 1,313 (3.7%)
Internal medicine (Internist) 18,405 (63.6%) 23,606 (66.4%)
Family/General medicine 4,018 (13.9%) 4,078 (11.5%)
Surgery general 1,225 (4.2%) 321 (0.9%)
Other/Unknown 4,612 (15.9%) 6,232 (17.5%)
Admission source1, n (%)
Physician referral 15,653 (54.1%) 18,047 (50.8%)
Clinical referral 1,401 (4.8%) 1,237 (3.5%)
Transfer from hospital 1,081 (3.7%) 2,480 (7.0%)
Other source 10,818 (37.4%) 13,786 (38.8%)
Admission site1, n (%)
Emergency room 19,877 (68.7%) 23,143 (65.1%)
ntensive care unit 1,669 (5.8%) 7,132 (20.1%)
Other site 7,407 (25.6%) 5,275 (14.8%)
Degree of severity1,2, n (%)
Minor 7,556 (26.1%) 7,203 (20.3%)
Moderate 10,715 (37.0%) 13,490 (37.9%)
Major 9,241 (31.9%) 10,628 (29.9%)
Extreme 1,441 (5.0%) 4,229 (11.9%)
Year of index date1, n (%)
2009 9,148 (31.6%) 10,203 (28.7%)
2010 5,999 (20.7%) 7,131 (20.1%)
2011 6,042 (20.9%) 7,922 (22.3%)
2012 6,548 (22.6%) 8,588 (24.2%)
2013 1,216 (4.2%) 1,706 (4.8%)
Notes:
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism.
1 Evaluated during index hospitalization stay.
2 Severity level for the admission diagnosis-related group, as deﬁnedby3M’s algorithm
(APR-DRG grouper code).
Table 2
Length of Stay and Treatment Characteristics of DVT and PE Patients.
Treatment Characteristics1 DVT PE
(N = 28,953) (N = 35,550)
Length of stay, mean [median] (SD) 4.7 [4] (4.5) 5.4 [5] (4.6)
Percentage of patients with an ICU stay, n (%) 2,857 (9.9%) 8,587 (24.2%)
Number of days in ICU, mean [median] (SD)
Overall population 0.3 [0] (1.6) 0.8 [0] (2.4)
Among patients with an ICU stay 3.0 [2] (4.1) 3.3 [2] (3.9)
Medication used, mean [median] (SD)
Number of different medications 6.6 [6] (4.0) 7.2 [7] (4.2)
Number of doses per day
Oral 9.6 [8.0] (21.9) 9.7 [8.2] (7.2)
Injections 3.3 [3] (2.4) 3.7 [3] (2.8)
Days to anticoagulant administration,
mean [median] (SD)
1.3 [1] (0.9) 1.3 [1] (1.0)
First administration of anticoagulant
therapy on day 3 or later, n (%)
1,007 (3.5%) 1,246 (3.5%)
Anticoagulant agent(s) administered on the
ﬁrst day of anticoagulant therapy2, n (%)
Warfarin 13,587 (46.9%) 16,029 (45.1%)
Unfractionated heparin 10,611 (36.6%) 16,166 (45.5%)
Low molecular weight heparins 18,044 (62.3%) 20,339 (57.2%)
Other 1,203 (4.2%) 1,314 (3.7%)
Notes:
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism, ICU:
intensive care unit.
1 Evaluated during index hospitalization stay.
2 The Premier Perspective Comparative Hospital Database does not provide the
anticoagulant administration sequence within the same day. Therefore, if two or more
agents were administered the same day it was not possible to identify which one was
administered ﬁrst.
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DVT cohort and $11,486 (14,784) in the PE cohort (Table 3a).
Table 3b presents costs for DVT and PE patients that had an ICU stay
during their hospitalization. Mean (SD) daily costs for these subgroups
were higher than those of the entire cohort with $3,255 (2,378) and$2,340 (1,827) for DVT and PE patients, respectively. For both sub-
samples, daily costs stabilized on the ﬁfth day compared to the third
day in the whole cohort (standardized difference DVT: 4.5%; PE: 5.2%;
Table 3b). The mean (SD) total hospitalization costs for DVT patients
with an ICU staywere 2.5 times higher than those of the overall popula-
tion at $24,692 (26,498). For PE patients with an ICU stay, the mean
(SD) total hospitalization costs were $19,901 (24,506).
The mean daily total hospitalization costs for DVT patients that had
an ICU stay (N = 2,857) were qualitatively higher compared to those
for PE patients that had an ICU stay (N= 8,587), especially for surgery
and supply costs (Table 3b). The mean (SD) surgery costs for DVT pa-
tients were $2,483 (4,070) compared to only $734 (2,093) for PE pa-
tients. A breakdown of mean surgery costs for DVT patients showed
that $1,625 was related to cardiovascular artery and vein surgeries
and $737 to surgery time (data not shown). The corresponding mean
costs for PE patients were $370 and $267, respectively. Mean (SD) sup-
ply costs were also higher for DVT compared to PE patients at $3,345
(4,532) and $1,206 (3,142), respectively. Supply cost components for
DVT patients revealed that $2,477 were for medical and surgical supply
costs, while those costs were $792 for PE patients (data not shown).
Table 4a presents daily pharmacy costs stratiﬁed by the top ﬁve
medications used by DVT and PE patients during their hospitalization.
For both cohorts, pharmacy costs were stable during thewhole hospital
stay. The most expensive day was the second day for DVT patients and
the admission day for PE patients. The major component of pharmacy
costs was injectable anticoagulant with an average daily cost ranging
from $60 to $83 for DVT and PE patients during the ﬁrst seven days of
the hospitalization. Daily pharmacy costs excluding anticoagulants
were also expensive; representing around 60% of the daily pharmacy
costs and ranging from $97 to $150 for DVT patients and from $85 to
$211 for PE patients in the ﬁrst seven days of the hospital stay
(Table 4a).
Daily pharmacy costs were also reported for the sub-population of
DVT and PE patients that experienced an ICU stay during their
Table 3a
Daily Hospitalization Costs of DVT and PE Patients.
All costs Room and board
costs1
Nursing
costs1
Surgery
costs1
Supply
costs1
Laboratory
costs1
Pharmacy
costs1
Other costs
Day(s) N Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
DVT patients 1 28,953 $2,321 (2,476) $942 (970) $28 (103) $84 (607) $127 (807) $196 (254) $185 (552) $759 (917)
2 28,612 $1,875 (2,507)⁎ $822 (731)⁎ $14 (110)⁎ $127 (651) $199 (911) $152 (231)⁎ $235 (689) $326 (764)⁎
3 25,222 $1,558 (2,245)⁎ $752 (670)⁎ $12 (108) $103 (565) $159 (821) $99 (162)⁎ $195 (652) $238 (712)⁎
4 20,567 $1,398 (2,180) $715 (693) $12 (99) $90 (722) $123 (744) $80 (134)⁎ $177 (670) $200 (604)
5 15,892 $1,297 (1,970) $688 (716) $11 (94) $73 (516) $106 (700) $72 (103) $170 (661) $177 (549)
6 11,725 $1,263 (1,967) $675 (748) $11 (95) $67 (498) $103 (779) $71 (112) $163 (542) $173 (521)
7 8,326 $1,274 (2,226) $669 (850) $12 (128) $73 (778) $98 (650) $73 (118) $160 (581) $188 (659)
8-142 5,732 $1,454 (118) $746 (58) $14 (1) $88 (18) $98 (14) $75 (4) $210 (29) $222 (21)
15-302 832 $1,733 (183) $887 (77) $17 (4) $75 (38) $114 (70) $82 (9) $288 (48) $269 (41)
N302 82 $1,556 (1,352) $719 (467) $10 (80) $69 (200) $136 (700) $75 (77) $309 (378) $238 (318)
Overall3 28,953 $1,594 (1,346) $714 (500) $15 (80) $87 (353) $131 (421) $121 (111) $179 (357) $347 (439)
Total4 28,953 $9,407 (12,731) $4,422 (5,835) $87 (676) $522 (1,815) $764 (2,261) $644 (763) $1,115 (3,437) $1,852 (2,809)
PE patients 1 35,550 $2,981 (2,602) $1,118 (986) $47 (146) $61 (500) $107 (754) $293 (322) $282 (890) $1,071 (1,088)
2 35,163 $2,034 (1,971)⁎ $1,010 (803)⁎ $22 (145)⁎ $62 (473) $111 (563) $198 (274)⁎ $229 (656) $401 (667)⁎
3 32,613 $1,564 (1,682)⁎ $886 (745)⁎ $17 (124) $41 (326) $80 (430) $117 (189)⁎ $178 (417) $244 (922)⁎
4 27,969 $1,421 (1,479) $829 (716) $16 (119) $38 (339) $72 (510) $94 (143)⁎ $169 (359) $205 (457)
5 23,003 $1,335 (1,702) $781 (747) $15 (116) $31 (257) $65 (436) $85 (221) $159 (415) $198 (1,005)
6 18,000 $1,276 (1,512) $744 (819) $14 (120) $31 (272) $65 (478) $79 (116) $154 (424) $189 (439)
7 13,251 $1,284 (2,193) $731 (905) $14 (120) $35 (335) $63 (390) $80 (137) $168 (1,465) $193 (476)
8-142 9,420 $1,533 (148) $828 (71) $17 (1) $45 (10) $82 (10) $82 (4) $221 (40) $258 (28)
15-302 1,428 $2,109 (164) $1,099 (78) $19 (3) $58 (20) $92 (33) $95 (8) $389 (67) $357 (40)
N302 165 $1,694 (1,136) $852 (565) $19 (115) $36 (124) $103 (339) $70 (59) $284 (549) $329 (390)
Overall3 35,550 $1,735 (1,211) $830 (516) $23 (104) $39 (201) $78 (371) $152 (130) $194 (376) $419 (514)
Total4 35,550 $11,486 (14,784) $5,778 (7,462) $142 (1,083) $293 (1,227) $551 (1,819) $895 (908) $1,346 (4,967) $2,480 (4,340)
Notes
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism.
⁎ Denotes statistical difference (i.e., standardized difference N10%) to the preceding day.
1 Cost stratiﬁcations were generated from the standardized chargesmaster codes categories of the billing information included in the Premier Perspective Comparative Hospital database.
2 Calculated as the average of the mean daily cost of the days included in the period.
3 Calculated as the mean daily costs per patient.
4 Calculated as the mean total hospitalization costs per patient.
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this subgroup than for the whole cohort ranging from $301 to $711
for DVT and from $196 to $560 for PE patients. As opposed to the entireDVT: deep vein thrombosis; N: Number of patients 
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seven days of the hospitalization, daily pharmacy costs of patients
with an ICU stay were not stable at the beginning of the hospital stay8 9 10 11 12 13 14
6 5,732 3,978 2,860 2,121 1,626 1,268 1,025
Other costs
Supply costs
Nursing costs
All costs
uring the First 14 Days. DVT: deep vein thrombosis; N: Number of patients.
PE: pulmonary embolism; N: Number of patients 
Day
N =
1 2 3 4 5 6 7 8 9 10 11 12 13 14
35,550 35,163 32,613 27,969 23,003 18,000 13,251 9,420 6,678 4,815 3,624 2,784 2,215 1,774
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
D
ai
ly
 c
os
t
Other costs Pharmacy costs
Laboratory costs Supply costs
Surgery costs Nursing costs
Room and board costs All costs
Fig. 3. Daily Hospitalization Costs of PE Patients Stratiﬁed by Cost Categories during the First 14 Days. PE: pulmonary embolism; N: Number of patients.
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pharmacy costs for DVT patients were $3,484 (7,027) compared to
$2,666 (9,267) for PE patients. The breakdown of pharmacy costs forTable 3b
Daily Hospitalization Costs of DVT and PE Patients with an ICU Stay.
All costs Room and
board costs1
Nursing
costs1
Su
Day(s) N Mean (SD) Mean (SD) Mean (SD) M
DVT patients
with an ICU
stay
1 2,857 $4,371 (4,771) $1,369 (942) $45 (161)
2 2,843 $4,699 (4,956) $1,345 (841) $34 (200)
3 2,733 $3,695 (4,411)⁎ $1,191 (902)⁎ $31 (210)
4 2,445 $2,907 (4,325)⁎ $1,075 (842)⁎ $26 (170)
5 2,133 $2,352 (3,328)⁎ $972 (756)⁎ $19 (135)
6 1,785 $2,206 (3,180) $947 (862) $19 (129)
7 1,467 $2,110 (3,865) $933 (769) $23 (242)
8-142 1,191 $1,988 (97) $918 (54) $16 (2)
15-302 285 $2,078 (274) $1,002 (75) $14 (5)
N302 43 $1,777 (1,715) $744 (550) $17 (111)
Overall3 2,857 $3,255 (2,378) $1,064 (464) $26 (125)
Total4 2,857 $24,692 (26,498) $9,096 (11,465) $209 (1,281) $2
PE patients
with an ICU
stay
1 8,587 $4,354 (4,085) $1,618 (1,059) $60 (196)
2 8,463 $3,106 (3,023)⁎ $1,445 (941)⁎ $36 (210)⁎
3 8,203 $2,218 (2,054)⁎ $1,222 (926)⁎ $26 (173)
4 7,712 $1,935 (2,104)⁎ $1,069 (843)⁎ $23 (165)
5 6,931 $1,700 (1,719)⁎ $965 (824)⁎ $20 (155)
6 5,915 $1,607 (1,838) $904 (894) $19 (161)
7 4,762 $1,642 (3,110) $887 (985) $18 (148)
8-142 3,695 $1,862 (134) $976 (62) $19 (1)
15-302 875 $2,328 (159) $1,184 (75) $21 (3)
N302 131 $1,799 (1,126) $893 (562) $24 (129)
Overall3 8,587 $2,340 (1,827) $1,100 (568) $29 (139)
Total4 8,587 $19,901 (24,506) $9,771 (12,067) $239 (1,862)
Notes:
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism.
⁎ Denotes statistical difference (i.e., standardized difference N10%) to the preceding day.
1 Cost stratiﬁcationswere generated from the standardized chargemaster code categories of th
2 Calculated as the average of the mean daily cost of the days included in the period.
3 Calculated as the mean daily costs per patient.
4 Calculated as the mean total hospitalization costs per patient.DVT patients showed that $1,430 were for ﬁbrinolytic agents and $637
for injectable anticoagulant agents, while corresponding results were
$516 and $770, respectively, for PE patients.rgery costs1 Supply costs1 Laboratory
costs1
Pharmacy
costs1
Other costs
ean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
$397 (1,266) $565 (1,501) $257 (317) $516 (1,264) $1,223 (1,787)
$588 (1,400)⁎ $837 (1,813)⁎ $230 (289) $711 (1,623)⁎ $955 (1,558)⁎
$444 (1,193)⁎ $658 (1,747)⁎ $164 (190)⁎ $502 (1,187)⁎ $705 (1,493)⁎
$350 (1,763) $405 (1,376)⁎ $135 (192)⁎ $397 (1,291) $519 (1,174)⁎
$233 (995) $317 (1,286) $111 (127)⁎ $319 (888) $381 (864)⁎
$194 (894) $293 (1,187) $103 (126) $310 (1,007) $340 (720)
$204 (1,711) $214 (973) $105 (136) $301 (1,191) $330 (1,107)
$165 (32) $162 (32) $97 (5) $308 (37) $322 (32)
$99 (57) $188 (140) $98 (9) $341 (54) $335 (52)
$113 (267) $231 (961) $89 (89) $276 (270) $307 (387)
$377 (734) $509 (769) $158 (115) $447 (651) $674 (841)
,483 (4,070) $3,345 (4,532) $1,222 (1,533) $3,484 (7,027) $4,853 (6,224)
$174 (843) $250 (1,396) $342 (362) $560 (1,648) $1,351 (1,620)
$155 (794) $236 (957) $260 (336)⁎ $388 (1,153)⁎ $586 (940)⁎
$85 (490)⁎ $138 (586)⁎ $155 (228)⁎ $251 (614)⁎ $341 (655)⁎
$74 (508) $122 (863) $122 (173)⁎ $226 (507) $298 (609)
$49 (343) $93 (450) $104 (132)⁎ $204 (560) $265 (526)
$48 (382) $92 (640) $95 (123) $196 (564) $253 (525)
$55 (476) $85 (440) $97 (176) $234 (2,389) $266 (565)
$62 (18) $109 (19) $95 (4) $278 (41) $323 (29)
$60 (23) $108 (42) $102 (10) $451 (74) $401 (43)
$28 (63) $102 (333) $76 (62) $310 (604) $366 (414)
$86 (303) $147 (670) $170 (145) $299 (648) $508 (674)
$734 (2,093) $1,206 (3,142) $1,313 (1,341) $2,666 (9,267) $3,973 (5,507)
e billing information included in the Premier PerspectiveTMComparativeHospital database.
Table 4a
Daily Hospitalization Pharmacy Costs of DVT and PE Patients.
All pharmacy
costs
Anticoagulant costs1 Fibrinolytic
costs1
X-ray media
costs1
Hospital solution
IV costs1
Opioid
costs1
Other
pharmacy
costs
All Oral Injectable2
Day(s) N Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean
(SD)
Mean (SD)
DVT patients 1 28,953 $185 (552) $73 (256) $1.01 (2.40) $71 (254) $39 (408) $19 (130) $8 (27) $4 (14) $41 (182)
2 28,612 $235 (689) $85 (283) $1.53 (3.06)⁎ $83 (282) $58 (553) $17 (140) $10 (30) $7 (18)⁎ $58 (202)
3 25,222 $195 (652) $78 (299) $1.54 (2.85) $75 (297) $39 (389) $11 (93) $9 (25) $6 (18) $53 (366)
4 20,567 $177 (670) $72 (297) $1.57 (3.13) $69 (296) $26 (338) $8 (90) $8 (23) $6 (18) $58 (474)
5 15,892 $170 (661) $68 (301) $1.53 (3.04) $65 (299) $21 (278) $7 (69) $8 (24) $6 (18) $61 (494)
6 11,725 $163 (542) $65 (351) $1.48 (3.11) $63 (348) $19 (269) $6 (70) $7 (22) $6 (18) $60 (266)
7 8,326 $160 (581) $63 (310) $1.46 (3.65) $60 (308) $18 (343) $4 (71) $8 (37) $6 (17) $61 (174)
8-143 5,732 $210 (29) $70 (5) $1.31 (0.10) $68 (5) $16 (14) $6 (3) $10 (2) $8 (1) $98 (20)
15-303 832 $288 (48) $82 (27) $1.08 (0.20) $77 (29) $2.36 (3.68) $2 (2) $15 (2) $12 (2) $174 (45)
N303 82 $309 (378) $43 (104) $1.17 (3.33) $41 (103) $10 (85) $2 (13) $17 (30) $15 (22) $222 (330)
Overall4 28,953 $179 (357) $76 (218) $1.41 (2.16) $73 (217) $32 (214) $11 (49) $7 (18) $5 (14) $48 (145)
Total5 28,953 $1,115 (3,437) $421 (2,104) $7.93 (14.29) $406 (2,089) $186 (1,240) $61 (298) $51 (193) $36 (135) $361 (1,738)
PE patients 1 35,550 $282 (890) $71 (166) $1.05 (2.43) $70 (165) $79 (790) $48 (185) $12 (34) $6 (16) $66 (268)
2 35,163 $229 (656) $85 (228) $1.75 (2.90)⁎ $83 (227) $37 (536) $12 (88)⁎ $12 (69) $7 (20) $75 (258)
3 32,613 $178 (417) $82 (266) $1.77 (3.26) $79 (265) $9 (214) $8 (80) $9 (32) $6 (18) $64 (205)
4 27,969 $169 (359) $78 (214) $1.81 (3.11) $75 (214) $6 (151) $5 (73) $8 (31) $5 (18) $65 (218)
5 23,003 $159 (415) $74 (317) $1.79 (3.51) $72 (317) $4 (142) $5 (113) $8 (30) $5 (17) $64 (176)
6 18,000 $154 (424) $67 (324) $1.67 (3.67) $64 (324) $3 (90) $4 (62) $8 (32) $5 (15) $69 (232)
7 13,251 $168 (1,465) $62 (338) $1.62 (3.60) $60 (337) $3 (94) $2 (28) $8 (39) $5 (16) $87 (1,417)
8-143 9,420 $221 (40) $83 (20) $1.39 (0.13) $81 (20) $4 (2) $3 (1) $12 (2) $7 (1) $112 (17)
15-303 1,428 $389 (67) $165 (49) $1.20 (0.22) $163 (49) $4.34 (3.02) $3 (4) $22 (5) $10 (1) $186 (26)
N303 165 $284 (549) $80 (461) $0.91 (1.74) $79 (461) $2 (8) $1 (10) $20 (61) $9 (19) $172 (207)
Overall4 35,550 $194 (376) $77 (184) $1.64 (2.17) $75 (184) $23 (221) $16 (57) $9 (26) $6 (14) $63 (213)
Total5 35,550 $1,346 (4,967) $512 (4,044) $10.09 (16.35) $497 (4,043) $139 (1,063) $81 (279) $67 (261) $39 (140) $508 (2,141)
Notes:
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism, IV: intravenous.
⁎ Denotes statistical difference (i.e., standardized difference N10%) to the preceding day.
1 Pharmacy costs stratiﬁcations were generated from the standardized charges master codes categories of the billing information included in the Premier Perspective
Comparative Hospital database.
2 Includes heparins and heparin-like agents such as low molecular weight heparin and synthetic heparinoid.
3 Calculated as the average of the mean daily cost of the days included in the period.
4 Calculated as the mean daily costs per patient.
5 Calculated as the mean total hospitalization costs per patient.
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Based on real-world data, this large retrospective studywas conduct-
ed to quantify the progression of daily hospitalization costs among pa-
tients receiving anticoagulant therapy with an admitting/primary
diagnosis of DVT or PE. A total of 28,953 DVT and 35,550 PE patients,
identiﬁed from January 2009 to March 2013, were studied. Overall,
DVT patients incurred costs on average of $1,594 per hospitalization
day, while PE patients accounted for $1,735 of costs per day. For both co-
horts, costs stabilized on the third day of hospitalization (DVT: $1,558;
PE: $1,564) with pharmacy costs remaining stable throughout the hos-
pital stay. The 10% of DVT and 24% of PE patients with an ICU episode
during their hospital stay incurred much higher total and daily costs
compared to the overall population and their costs took longer to
stabilize.
In the literature, the prevalence of DVT is higher than PE, which was
not the case in our sample of patients [1,14]. This suggests that our sam-
ple of DVT patients may not reﬂect the entire DVT population and could
represent a more severe population. In the subsample of patients with
an ICU stay during their hospitalization, higher daily and overall costs
were found for DVT patients compared to PE patients. The cost break-
down for DVT and PE patients with an ICU stay showed that DVT pa-
tients had qualitatively higher surgery, supply, and pharmacy costs
relative to PE patients, while other cost components (i.e., room and
board, nursing, and laboratory costs) were more similar. The degree of
severity of the admissions was investigated and was lower for DVT
versus PE patientswith an ICU stay in the current study. AmongDVT pa-
tients with an ICU stay, 480 (16.8%) had an extreme degree of severity
compared to 2,386 (27.9%) for corresponding PE patients. This suggests
that DVT patients with an ICU stay required more expensive carecompared to PE patients with an ICU stay, even if PE is a more life-
threatening condition.
To the best of our knowledge, this study is the ﬁrst to quantify the
progression of daily costs among hospitalized patients with an admit-
ting/primary diagnosis of DVT or PE. Spyropoulos et al. (2007) used
the Integrated Health Care Information Service National Managed Care
database to quantify the total hospitalization cost of patients with a pri-
mary diagnosis of DVT or PE during the period from February 1998 to
June 2004 [15]. The authors found an initial hospitalization cost of
$9,805 for DVT patients and $14,146 for PE patients. More recently,
Lefebvre et al. (2012) used data from the Ingenix National Managed
Care database between January 2004 and December 2008 to assess
the annual healthcare cost of VTE patients. The authors reported an an-
nual healthcare cost of $33,531, of which 51% was related to hospital
stays [5]. Our results are similar to the ﬁndings of these two studies
and concur with the literature that VTEs lead to important healthcare
costs.
With a signiﬁcant part of healthcare costs linked to hospitalizations,
new anticoagulation therapies can offer alternative options inmanaging
DVT and PE. Recent studies have evaluated the impact of target-speciﬁc
oral anticoagulants versus the standard of care on hospital LOS among
VTE and NVAF patients [7–9]. These authors reported that patients
treated with target-speciﬁc oral anticoagulants had a signiﬁcantly
shorter LOS compared to patients receiving the standard of care. Our re-
sults suggest that LOS is a major cost driver in hospitalization and any
reduction in the LOSmay translate into relatively important cost savings
for both DVT and PE cohorts.
The Joint Commission reported in the National Patient Safety
Goals that anticoagulation therapy is more likely than other treat-
ments to cause complications due to complex dosing, insufﬁcient
Table 4b
Daily Hospitalization Pharmacy Costs of DVT and PE Patients with an ICU Stay.
All pharmacy
costs
Anticoagulant costs1 Fibrinolytic
costs1
Xray media
costs1
Hospital
solution IV
costs1
Opioid
costs1
Other
pharmacy
costs
All Oral Injectable2
Day(s) N Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
DVT patients
with an ICU
stay
1 2,857 $516 (1,264) $64 (282) $0.58 (2.15) $62 (282) $314 (1,167) $42 (179) $21 (58) $10 (23) $64 (184)
2 2,843 $711 (1,623)⁎ $73 (396) $0.97 (2.03)⁎ $69 (393) $435 (1,478) $57 (336) $29 (65)⁎ $16 (31)⁎ $101 (289)⁎
3 2,733 $502 (1,187)⁎ $75 (379) $1.14 (2.21) $72 (378) $259 (982)⁎ $43 (230) $23 (47)⁎ $13 (26) $89 (250)
4 2,445 $397 (1,291) $66 (211) $1.23 (2.24) $62 (201) $170 (906) $27 (155) $18 (41)⁎ $11 (24) $105 (859)
5 2,133 $319 (888) $64 (212) $1.25 (2.41) $61 (205) $110 (648) $20 (143) $16 (46) $11 (23) $97 (471)
6 1,785 $310 (1,007) $81 (663) $1.24 (2.65) $77 (656) $92 (610) $17 (138) $15 (37) $10 (23) $94 (312)
7 1,467 $301 (1,191) $87 (547) $1.26 (3.22) $83 (545) $82 (789) $10 (92) $17 (79) $10 (22) $94 (228)
8-143 1,191 $308 (37) $97 (15) $1.19 (0.09) $95 (15) $52 (48) $5 (2) $16 (2) $12 (0) $125 (16)
15-303 285 $341 (54) $126 (55) $0.81 (0.17) $115 (57) $4.36 (10.55) $4 (4) $19 (2) $13 (1) $175 (27)
N303 43 $276 (270) $28 (48) $0.67 (1.27) $27 (49) $18 (117) $4 (18) $18 (35) $12 (17) $195 (205)
Overall4 2,857 $447 (651) $71 (250) $1.15 (1.76) $68 (249) $233 (548) $31 (98) $19 (34) $12 (19) $81 (168)
Total5 2,857 $3,484 (7,027) $665 (3,786) $8.86 (14.88) $637 (3,737) $1,430 (3,359) $208 (679) $166 (468) $99 (220) $917 (3,612)
PE patients with
an ICU stay
1 8,587 $560 (1,648) $63 (234) $0.61 (1.73) $62 (234) $311 (1,549) $55 (250) $21 (54) $6 (17) $103 (336)
2 8,463 $388 (1,153)⁎ $80 (275) $1.40 (2.64)⁎ $78 (275) $131 (996)⁎ $18 (116)⁎ $24 (66) $9 (21)⁎ $128 (470)
3 8,203 $251 (614)⁎ $86 (382) $1.62 (2.93) $83 (382) $30 (363)⁎ $11 (130) $18 (55) $7 (19) $99 (242)
4 7,712 $226 (507) $81 (270) $1.72 (3.06) $78 (269) $19 (256) $7 (108) $15 (52) $7 (18) $97 (303)
5 6,931 $204 (560) $77 (418) $1.74 (3.22) $74 (418) $9 (206) $6 (130) $13 (46) $6 (18) $92 (262)
6 5,915 $196 (564) $73 (477) $1.60 (3.04) $71 (477) $7 (148) $5 (78) $13 (46) $6 (17) $92 (225)
7 4,762 $234 (2,389) $71 (471) $1.52 (2.88) $69 (471) $5 (148) $3 (40) $14 (58) $6 (19) $135 (2,332)
8-143 3,695 $278 (41) $104 (28) $1.28 (0.13) $102 (28) $7 (4) $3 (1) $16 (2) $8 (1) $140 (15)
15-303 875 $451 (74) $203 (61) $1.05 (0.22) $201 (61) $4.92 (4.67) $3 (5) $25 (6) $10 (2) $204 (22)
N303 131 $310 (604) $94 (517) $0.80 (1.49) $93 (517) $2 (9) $2 (11) $23 (68) $8 (13) $181 (213)
Overall4 8,587 $299 (648) $77 (281) $1.46 (2.03) $74 (281) $84 (412) $17 (65) $16 (36) $6 (14) $100 (376)
Total5 8,587 $2,666 (9,267) $789 (7,646) $11.67 (19.33) $770 (7,645) $516 (2,009) $110 (410) $147 (472) $62 (208) $1,042 (3,930)
Notes:
SD: standard deviation, DVT: deep vein thrombosis, PE: pulmonary embolism, IV: intravenous.
⁎ Denotes statistical difference (i.e., standardized difference N10%) to the preceding day.
1 Pharmacy costs stratiﬁcations were generated from the standardized charges master codes categories of the billing information included in the Premier Perspective Com
parative Hospital database.
2 Includes heparins and heparin-like agents such as low molecular weight heparin and synthetic heparinoid.
3 Calculated as the average of the mean daily cost of the days included in the period.
4 Calculated as the mean daily costs per patient.
5 Calculated as the mean total hospitalization costs per patient.
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dard of care (i.e., low molecular weight heparin/VKA), for example,
requires frequent laboratory INR monitoring and warfarin dosage
titration because of its variability in dose response [17,19]. Further-
more, our ﬁndings that our sample of VTE patients received seven
drugs, on average and were administered 13 doses per day can po-
tentially increase the incidence of medication errors and adverse
drug events. On the other hand, target-speciﬁc oral anticoagulants
have a more predictable dose response and are administered once
or twice daily in ﬁxed doses andwithout routine laboratorymonitor-
ing, giving patients the advantage of a potentially shorter duration of
hospitalization. It was reported in a recent review by Dobesh that
these advantages could reduce the costs on the health care system
by potentially preventing recurrent VTE and its complications [20].
Furthermore, it was shown in a recent study that the use of a bridging
agent, which is not necessary for target-speciﬁc oral anticoagulants,
prolonged hospital LOS [21]. These advantages of target-speciﬁc oral
anticoagulants may offset their higher acquisition cost by decreasing
pharmacy and labor costs related to the administration of bridging
agents and frequent INR monitoring. In addition, pharmacy costs ex-
cluding anticoagulant agents were high and any reduction in LOS
would impact the cost of these other medications used by patients dur-
ing their hospitalization.
This studywas subject to some limitations. Aswith any study based on
healthcare databases, the data may have contained inaccuracies or omis-
sions in coded procedures, diagnoses, or pharmacy claims. Also, both the
admitting pattern and the costing model of the current study are speciﬁc
to the United States. A recent study by Van Bellen and colleagues that
used data from the EINSTEIN DVT and EINSTEIN PE trials including studycenters from Western Europe, Eastern Europe, North America, South
America, Israel, Australia andNewZealand, Asia, and SouthAfrica reported
that North America had lower admission rates compared to other regions
of theworld [22]. Asmentioned by the authors, in North America only 19%
of patients with DVT were admitted to the hospital as compared to 85%
in South America. Higher hospitalization rates were reported in regions
such as Eastern Europe (i.e., 94% for PE and 82% for DVT) that may be
caused by concerns regarding bleeding risk and possible complications in
patients with VTE, or a reduced awareness about best practices in VTE
management [22,23]. In addition, the observational design could have
been susceptible to various biases such as information or classiﬁcation
bias (e.g., identiﬁcation of false-positive DVT or PE events). It is also possi-
ble that DVT or PE events in the database’s claims were undercoded
(i.e., false-negative). Despite these limitations, the current research con-
tributes to the existing literature by providing valuable information with
real-life scenarios and a large sample size.Conclusion
This study found that hospitalization costs of DVT and PE patients
were high in the ﬁrst three days and stabilized thereafter. In addition,
patients with an ICU stay during their hospitalization had higher costs
than the overall population. This effect was more pronounced in the
DVT population with twofold higher hospitalization costs which may
suggest a higher acuity of the DVT patients that get hospitalized. The re-
sults of this study suggest that any change in treatment strategies or
protocols that could affect LOS may impact the hospitalization costs of
DVT and PE populations.
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